{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T03:55:30Z","timestamp":1767585330011},"reference-count":18,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.vaccine.2017.02.039","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T02:45:36Z","timestamp":1489113936000},"page":"1844-1855","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The ADVANCE Code of Conduct for collaborative vaccine studies"],"prefix":"10.1016","volume":"35","author":[{"given":"Xavier","family":"Kurz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bauchau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Glismann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieke Maria","family":"van der Aa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Simondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.02.039_b0005","unstructured":"European Medicines Agency (EMA), Pandemic report and lessons learned. Outcome of the European Medicines Agency's activities during the 2009 (H1N1) flu pandemic (EMA\/221017\/2011); 29 April 2011. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2011\/04\/WC500105820.pdf> [accessed 30.01.2017]."},{"issue":"26","key":"10.1016\/j.vaccine.2017.02.039_b0010","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1016\/j.vaccine.2011.04.005","article-title":"Safety monitoring of Influenza A\/H1N1 pandemic vaccines in EudraVigilance","volume":"29","author":"Kurz","year":"2011","journal-title":"Vaccine"},{"issue":"9707","key":"10.1016\/j.vaccine.2017.02.039_b0015","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccins","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.02.039_b0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000184748","article-title":"The epidemiology of Guillain-Barr\u00e9 worldwide. A systematic literature review","volume":"32","author":"McGrogan","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"39","key":"10.1016\/j.vaccine.2017.02.039_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.14.39.19345-en","article-title":"ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe","volume":"14","author":"Eurosurveillance Editorial Team","year":"2009","journal-title":"Eurosurveillance"},{"issue":"S","key":"10.1016\/j.vaccine.2017.02.039_b0030","first-page":"S327","article-title":"Risk of Guillain-Barr\u00e9 syndrome and vaccination against seasonal flu","volume":"19","author":"Grimaldi-Bensousa","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"S","key":"10.1016\/j.vaccine.2017.02.039_b0035","first-page":"S339","article-title":"Safety of pandemic flu vaccine in the population of Stockholm, Sweden: first, preliminary, data","volume":"19","author":"Bardage","year":"2010","journal-title":"Pharmacoepidemio Drug Saf"},{"key":"10.1016\/j.vaccine.2017.02.039_b0040","doi-asserted-by":"crossref","first-page":"e1000388","DOI":"10.1371\/journal.pmed.1000388","article-title":"Estimates of pandemic influenza vaccine effectiveness in Europe, 2009\u20132010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study","volume":"1","author":"Valenciano","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.02.039_b0045","unstructured":"Destefano F, Vellozzi C, Lessons learned exercise. ECDC vaccine adverse event surveillance and communication (VAESCO II) project; 2009\u20132011. <http:\/\/vaesco.net\/vaesco\/news> [accessed 30.01.2017]."},{"issue":"1","key":"10.1016\/j.vaccine.2017.02.039_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd4520","article-title":"The Innovative Medicines Initiative: an engine for regulatory science","volume":"14","author":"Goldman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2017.02.039_b0055","unstructured":"The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE). <http:\/\/www.advance-vaccines.eu\/> [accessed 30.01.2017]."},{"issue":"1","key":"10.1016\/j.vaccine.2017.02.039_b0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1867299X00002786","article-title":"Towards principles-based approaches to governance of health-related research using personal data","volume":"4","author":"Laurie","year":"2013","journal-title":"Eur J Risk Regul"},{"key":"10.1016\/j.vaccine.2017.02.039_b0065","author":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)"},{"key":"10.1016\/j.vaccine.2017.02.039_b0070","unstructured":"ADVANCE. Good practice guidance, Module 1: code of conduct. WP1 \u2013 best practice and code of conduct for benefit-risk monitoring of vaccines. Deliverable 1.6: Guidance on best practices draft, section 4.2, version 5 final; 2015 . <http:\/\/www.advance-vaccines.eu\/app\/archivos\/publicacion\/7\/ADVANCE_WP1_Deliverable-1_6_V5-Final.pdf> [accessed 30.01.2017]."},{"key":"10.1016\/j.vaccine.2017.02.039_b0075","author":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)"},{"key":"10.1016\/j.vaccine.2017.02.039_b0080","unstructured":"European Medicines Agency (EMA), The European Union electronic Register of Post-Authorisation Studies (EU PAS Register). <http:\/\/www.encepp.eu\/encepp_studies\/indexRegister.shtml> [accessed 30.01.2017]."},{"key":"10.1016\/j.vaccine.2017.02.039_b0085","author":"International Society for Pharmacoepidemiology (ISPE)"},{"key":"10.1016\/j.vaccine.2017.02.039_b0090","author":"International Epidemiological Association (IEA)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T12:35:43Z","timestamp":1529930143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17302426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0264410X17302426"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ADVANCE Code of Conduct for collaborative vaccine studies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}